Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

FLT3 inhibitor HM43239

A selective, reversible type I inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) with potential antineoplastic activity. Upon administration of FLT3 inhibitor HM43239, it reversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:FMS-like tyrosine kinase 3 inhibitor HM43239
Code name:HM 43239
HM-43239
HM43239
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search